JP5191036B2 - 抗ヒトテネイシンモノクローナル抗体 - Google Patents

抗ヒトテネイシンモノクローナル抗体 Download PDF

Info

Publication number
JP5191036B2
JP5191036B2 JP2007500356A JP2007500356A JP5191036B2 JP 5191036 B2 JP5191036 B2 JP 5191036B2 JP 2007500356 A JP2007500356 A JP 2007500356A JP 2007500356 A JP2007500356 A JP 2007500356A JP 5191036 B2 JP5191036 B2 JP 5191036B2
Authority
JP
Japan
Prior art keywords
antibody
derivative
fragment
recombinant
tenascin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007500356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008506355A5 (enExample
JP2008506355A (ja
Inventor
リタ・デ・サンティス
アンジェラ・ペッリッチャ
ジョヴァンナ・パロンボ
パオロ・カルミナティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2008506355A publication Critical patent/JP2008506355A/ja
Publication of JP2008506355A5 publication Critical patent/JP2008506355A5/ja
Application granted granted Critical
Publication of JP5191036B2 publication Critical patent/JP5191036B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2007500356A 2004-02-27 2005-02-16 抗ヒトテネイシンモノクローナル抗体 Expired - Fee Related JP5191036B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000105A ITRM20040105A1 (it) 2004-02-27 2004-02-27 Anticorpo monoclonale antitenascina umana.
ITRM2004A000105 2004-02-27
PCT/IT2005/000078 WO2005082938A2 (en) 2004-02-27 2005-02-16 Anti-human tenascin monoclonal antibody

Publications (3)

Publication Number Publication Date
JP2008506355A JP2008506355A (ja) 2008-03-06
JP2008506355A5 JP2008506355A5 (enExample) 2008-04-17
JP5191036B2 true JP5191036B2 (ja) 2013-04-24

Family

ID=34897820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007500356A Expired - Fee Related JP5191036B2 (ja) 2004-02-27 2005-02-16 抗ヒトテネイシンモノクローナル抗体

Country Status (15)

Country Link
US (1) US7989171B2 (enExample)
EP (1) EP1718678B1 (enExample)
JP (1) JP5191036B2 (enExample)
KR (1) KR101266389B1 (enExample)
CN (1) CN1946740B (enExample)
AR (1) AR047819A1 (enExample)
AU (1) AU2005217237B2 (enExample)
BR (1) BRPI0508082A8 (enExample)
CA (1) CA2558718C (enExample)
ES (1) ES2654065T3 (enExample)
IT (1) ITRM20040105A1 (enExample)
MX (1) MXPA06009674A (enExample)
PL (1) PL1718678T3 (enExample)
PT (1) PT1718678T (enExample)
WO (1) WO2005082938A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086769A2 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP2012031084A (ja) * 2010-07-29 2012-02-16 Tokyo Univ Of Science 抗腫瘍剤
WO2014113459A1 (en) * 2013-01-15 2014-07-24 Duke University Hiv-1 neutralizing factor
EP2999967B1 (en) 2013-05-21 2020-05-20 NX Pharmagen Use of tenascin-c as an extracellular marker of tumor-derived microparticles
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
GB201616596D0 (en) * 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN119019548B (zh) * 2022-07-05 2025-06-24 东莞市朋志生物科技有限公司 抗甲型流感病毒抗体、检测甲型流感病毒的试剂和试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5634076A (en) * 1994-10-04 1997-05-27 Analog Devices, Inc. DMA controller responsive to transition of a request signal between first state and second state and maintaining of second state for controlling data transfer
US6014709A (en) * 1997-11-05 2000-01-11 Unisys Corporation Message flow protocol for avoiding deadlocks
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
AU4682100A (en) * 1999-05-01 2000-11-17 University Of Medicine And Dentistry Of New Jersey Neurite outgrowth and guidance by tenascin-c
US7058750B1 (en) * 2000-05-10 2006-06-06 Intel Corporation Scalable distributed memory and I/O multiprocessor system
JP3646159B2 (ja) * 2001-02-08 2005-05-11 国立大学法人三重大学 抗テネイシンｃモノクローナル抗体及び当該抗体を産生するハイブリドーマ
ITRM20010079A1 (it) * 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
SI1478667T1 (sl) * 2002-02-26 2010-12-31 Sigma Tau Ind Farmaceuti Monoklonski protitelesni anti-äśloveĺ ki tenascin
ITRM20020128A1 (it) * 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
WO2005082938A2 (en) 2005-09-09
HK1100848A1 (en) 2007-09-28
EP1718678B1 (en) 2017-10-11
WO2005082938A3 (en) 2005-12-15
AU2005217237A1 (en) 2005-09-09
KR101266389B1 (ko) 2013-05-28
CA2558718C (en) 2015-01-13
ES2654065T3 (es) 2018-02-12
ITRM20040105A1 (it) 2004-05-27
AU2005217237B2 (en) 2011-12-22
BRPI0508082A (pt) 2007-07-17
PL1718678T3 (pl) 2018-05-30
CN1946740A (zh) 2007-04-11
CA2558718A1 (en) 2005-09-09
KR20070002029A (ko) 2007-01-04
US7989171B2 (en) 2011-08-02
JP2008506355A (ja) 2008-03-06
MXPA06009674A (es) 2007-03-21
BRPI0508082A8 (pt) 2017-12-26
PT1718678T (pt) 2017-12-29
US20100297003A1 (en) 2010-11-25
CN1946740B (zh) 2012-09-05
AR047819A1 (es) 2006-02-22
EP1718678A2 (en) 2006-11-08

Similar Documents

Publication Publication Date Title
US8048417B2 (en) Anti-human tenascin monoclonal antibody
US7090844B2 (en) Use of antibodies against the MUC18 antigen
US7067131B2 (en) Methods for using anti-MUC18 antibodies
EP1446418B1 (en) Integrin targeting compounds
US9765155B2 (en) Covalent disulfide-linked diabodies and uses thereof
CN100535013C (zh) 应用抗体分子对肿瘤血管进行选择性定向
JP5191036B2 (ja) 抗ヒトテネイシンモノクローナル抗体
CN116789836B (zh) 针对dll3的抗体及其用途
JP2004536578A (ja) 腫瘍ターゲティング用の抗−ｍｕｃ−１単鎖抗体
CN116574187B (zh) 针对gucy2c的抗体及其用途
TWI881873B (zh) 抗ｇｒｐ７８抗體及其應用
HK1100848B (en) Anti-human tenascin monoclonal antibody
CN118324916A (zh) 一种抗人gprc5d的单克隆抗体及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121102

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121204

TRDD Decision of grant or rejection written
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20121227

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121227

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130128

R150 Certificate of patent or registration of utility model

Ref document number: 5191036

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160208

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees